Core Viewpoint - Iridex Corporation plans to relocate its headquarters from Mountain View, California to San Jose, California, aiming to achieve significant cost savings and maintain operational efficiency [1][3]. Cost Savings - The company signed a non-binding letter of intent for a new lease on January 26, 2026, for a 31,000 square feet location, expecting to save approximately $0.4 million in fiscal year 2026 and about $0.6 million annually thereafter [2]. - The relocation is part of the company's commitment to reducing operating expenses, which has been a priority over the past year [3]. Operational Strategy - The move is expected to lower operating expenses while allowing the company to maintain reduced manufacturing operations and attract high-caliber talent in the Bay Area [3]. - Iridex Corporation is recognized as a leader in developing and marketing innovative laser-based medical systems for the ophthalmology market, with a focus on treating glaucoma and retinal diseases [4].

Core Insights - Iridex Corporation demonstrated continued revenue growth, operational efficiencies, and positive cash flow in its preliminary unaudited results for Q4 and full year 2025 [1][4] Fourth Quarter 2025 Results - Total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter [8] - The company achieved positive cash flow in the fourth quarter [8] - Sold 15,800 Cyclo G6 probes, an increase from 13,300 in the prior year quarter [8] - Sold 44 Cyclo G6 Glaucoma Laser Systems, slightly down from 47 in the prior year quarter [8] Full Year 2025 Results - Total revenue is expected to be between $52.5 million and $52.7 million, reflecting year-over-year growth of 8% compared to $48.7 million in 2024 [8] - The company expects to achieve positive adjusted EBITDA for the full year 2025 [8] - Sold 57,700 Cyclo G6 probes, an increase from 55,400 in the prior year [8] - Sold 133 Cyclo G6 Glaucoma Laser Systems, up from 125 in the prior year [8] Company Overview - Iridex Corporation is a leader in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market [5] - The company's proprietary MicroPulse technology offers safe and effective treatment for sight-threatening eye conditions [5]

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].